Sex-Specific Efficacy and Safety in HF Trials Inclusion Is Only the First Step

Sadiya Khan, Clyde W. Yancy, Gregg C. Fonarow*

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish (US)
Pages (from-to)70
Number of pages1
JournalJAMA cardiology
Volume10
Issue number1
DOIs
StatePublished - Jan 8 2025

Funding

Conflict of Interest Disclosures: Dr Khan reported grants from the National Heart, Lung, and Blood Institute and the American Heart Association outside the submitted work. Dr Fonarow reported receiving personal fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Edwards, Eli Lilly, Janssen, Johnson & Johnson, Medtronic, Merck, Novartis, and Pfizer outside the submitted work. No other disclosures were reported.

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this